Dark

Check out our Dark Pool Levels

CYTH
Cyclo Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Mar 25, 2025

0.7206USD+1.393%(+0.0099)188,267

Pre-market

0.00USD-100.000%(-0.71)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 20, 2022

08:05AM EST Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference Business Wire

Jan 13, 2022

02:23PM EST Cyclo Therapeutics Files For U.S. Patent Titled 'METHODS FOR TREATING ALZHEIMER'S DISEASE' Benzinga

Dec 9, 2021

08:05AM EST Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC(tm) Study Evaluating Trappsol(r) Cyclo(tm) for the Treatment of Niemann-Pick Disease Business Wire

Dec 6, 2021

08:45AM EST Cyclo Therapeutics, Inc. (CYTH) said on Monday that it has received necessary approval from the U.S. Food and Drug Administration or FDA for its initial investigational new drug or IND application to move ahead with the Phase 2 study of Trappsol Cyclo to treat early Alzheimer's disease. RTTNews

08:11AM EST Cyclo Receives IND Clearance From FDA To Advance Phase 2 Study Of Trappsol Cyclo For Treatment Of Alzheimer's Disease RTTNews

08:08AM EST Cyclo Therapeutics Receives IND Clearance From The U.S. FDA To Advance Its Phase 2 Study Of Trappsol Cyclo For The Treatment Of Alzheimer's Disease Benzinga

08:05AM EST Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol(r) Cyclo(tm) for the Treatment of Alzheimer's Disease Business Wire

Nov 19, 2021

12:54PM EST Cyclo Therapeutics Form 4 Filing From Co. Director Franics Ostronic Shows Purchase Of 10.652K Shares On Nov. 19 Benzinga

Nov 17, 2021

02:39PM EST Mid-Afternoon Market Update: Dow Falls 200 Points; Rockwell Medical Shares Spike Higher Benzinga

12:15PM EST Mid-Day Market Update: StoneCo Drops After Q3 Earnings; EyePoint Pharmaceuticals Shares Surge Benzinga

10:12AM EST Mid-Morning Market Update: Markets Down; Lowe's Earnings Beat Estimates Benzinga

07:53AM EST The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment Benzinga

05:40AM EST A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Speakers Benzinga

Nov 16, 2021

08:36PM EST Cyclo Therapeutics Prices Public Offering Of 1.95 Mln Shares At $6.00/shr RTTNews

08:28PM EST Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock Business Wire

04:28PM EST Cyclo Therapeutics Reports Offering Of Common Shares, No Size Disclosed Benzinga

04:27PM EST Cyclo Therapeutics Announces Proposed Public Offering of Common Stock Business Wire

10:29AM EST Shares of Cyclo Therapeutics, Inc. (CYTH) gapped up more than 5% on Tuesday morning. RTTNews

08:10AM EST Cyclo Therapeutics Submits Investigational New Drug Application To FDA To Advance Trappsol Cyclo In Phase 2 Study For Treatment Of Alzheimer's Disease Benzinga

08:05AM EST Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol(r) Cyclo(tm) in Phase 2 Study for Treatment of Alzheimer's Disease Business Wire

Nov 15, 2021

05:47PM EST Cyclo Therapeutics Q3 EPS $(0.60), Sales $403.90K Benzinga

04:20PM EST Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results Business Wire

Nov 10, 2021

08:05AM EST Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event Business Wire

Nov 2, 2021

08:05AM EDT Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer's Disease Asset Business Wire

Oct 19, 2021

09:15AM EDT Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment Business Wire

Oct 18, 2021

08:15AM EDT Cyclo Therapeutics Announces Abstract Accepted For Poster Presentation At 14th International Congress Of Inborn Errors Of Metabolism Benzinga

08:10AM EDT Cyclo Therapeutics Announces Abstract Accepted For Poster Presentation RTTNews

08:05AM EDT Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) Business Wire

Oct 6, 2021

08:05AM EDT Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab Business Wire

Sep 27, 2021

08:10AM EDT Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD As Chief Medical Officer Benzinga

Sep 15, 2021

08:05AM EDT Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit Business Wire

Sep 8, 2021

08:05AM EDT Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference Business Wire

Aug 17, 2021

08:16AM EDT Cyclo Therapeutics Q2 Net Loss $3.6 Mln Or $0.56/shr Vs. Loss $2.19 Mln Or $1.61/shr Prior Year RTTNews

08:12AM EDT Cyclo Therapeutics Monday Reported Q2 EPS $(0.56) Beats $(0.76) Estimate, Sales $238.59K Miss $358.00K Estimate Benzinga

08:05AM EDT Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results Business Wire

Aug 16, 2021

05:50PM EDT Cyclo Therapeutics 8-K Shows Co. Entered Equity Distribution Deal With Oppenheimer For Issuance, Sale Of Up To $20M Shares Benzinga

Jul 30, 2021

09:14AM EDT Cyclo Therapeutics Inc. (CYTH) announced new positive safety and efficacy data from ongoing phase 1 open-label extension study of trappsol cyclo for the treatment of niemann-pick disease type C1 or NPC. NPC is a rare, progressive and fatal genetic disorder characterized by abnormal accumulation of cholesterol in cells. RTTNews

09:00AM EDT Cyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In Genetic Disorder Benzinga

08:11AM EDT Cyclo Reports Positive Data Phase 1 Study Of Trappsol Cyclo For Treatment Of Niemann-Pick Disease Type C1 RTTNews

08:06AM EDT Cyclo Therapeutics Reports Safety, Efficacy Data From Ongoing Phase 1 Study Of Trappsol Cyclo For Treatment Of Niemann-Pick Disease Type C1 Benzinga

08:05AM EDT Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol(r) Cyclo(tm) for the Treatment of Niemann-Pick Disease Type C1 Business Wire

Jul 27, 2021

11:13AM EDT Cyclo Therapeutics Commences Commercial-Scale Manufacturing For Trappsol Cyclo Benzinga

Jun 21, 2021

08:05AM EDT Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation Business Wire

Jun 17, 2021

08:13AM EDT Cyclo Therapeutics Commences Patient Enrollment In Phase 3 Study Of Trappsol Cyclo In Niemann-Pick Type C1 RTTNews

08:06AM EDT Cyclo Therapeutics Commences Patient Enrollment In TransportNPC Pivotal Phase 3 Study Evaluating Trappsol Cyclo In Niemann-Pick Type C1 Benzinga

08:05AM EDT Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol(r) Cyclo(tm) in Niemann-Pick Type C1 Business Wire

Jun 15, 2021

08:06AM EDT Cyclo Therapeutics Highlights Launch Of New Website Benzinga

08:05AM EDT Cyclo Therapeutics Announces Launch of New Website Business Wire

Jun 14, 2021

08:10AM EDT Cyclo Therapeutics to Join the Russell 2000 Index Benzinga

08:05AM EDT Cyclo Therapeutics Announces Inclusion in the Russell 2000(r) Index Business Wire

Jun 9, 2021

08:05AM EDT Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference Business Wire

May 20, 2021

09:05AM EDT Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer's Disease Panel Business Wire

May 17, 2021

09:13AM EDT Cyclo Therapeutics Q1 Net Loss $4M Benzinga

09:05AM EDT Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results Business Wire

May 11, 2021

09:08AM EDT Cyclo Therapeutics Names Lori McKenna Gorski Global Head Of Patient Advocacy RTTNews

09:05AM EDT Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy Business Wire

Apr 27, 2021

09:07AM EDT Cyclo Therapeutics Announces Design Of Pivotal Phase 3 Study Evaluating Trappsol Cyclo In Niemann-Pick Type C1 Benzinga

09:05AM EDT Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol(r) Cyclo(tm) in Niemann-Pick Type C1 Business Wire

Apr 20, 2021

09:29AM EDT Cyclo Therapeutics To Proceed With IND Filing For Phase 2 Trial Using Intravenous Trappsol Cyclo In Alzheimer's Disease Benzinga

09:29AM EDT Cyclo Gets FDA Feedback Supporting Development Strategy To Submit IND Application For Phase 2 Study Of Trappsol Cyclo RTTNews

09:25AM EDT Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol(r) Cyclo(tm) in Alzheimer's Disease Business Wire

Mar 25, 2021

10:26AM EDT Cyclo Therapeutics shares were trading higher after the company announced the Phase 1/2 trial of Trappsol Cyclo in rare disease Niemann-Pick Type C1 met its primary endpoint. Benzinga

09:19AM EDT Cyclo Therapeutics, Inc. (CYTH) Thursday announced that its phase 1/2clinical trial using intravenous trappsol in Niemann-Pick Type C1 patients met primary endpoints. The double blind study was done in patients aged 2 to 39 years in clinical sites in the U.K., Israel Sweden. RTTNews

08:45AM EDT Cyclo Therapeutics Phase 1/2 Trial Of Trappsol Cyclo In Rare Disease Niemann-Pick Type C1 Met Primary Endpoint Benzinga

08:40AM EDT Cyclo Therapeutics Meets Primary Efficacy Endpoint In Phase 1/2 Trial From Intravenous Trappsol Cyclo RTTNews

08:35AM EDT Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol(r) Cyclo(tm) in Rare Disease Niemann-Pick Type C1 (NPC1) Business Wire

Mar 15, 2021

08:26AM EDT Cyclo Therapeutics Reports FY20 Net Loss ~$8.9M Benzinga

08:05AM EDT Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

Mar 12, 2021

08:05AM EST Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference Business Wire

Mar 10, 2021

08:43AM EST Cyclo Therapeutics Names Russ Belden As Acting COO Benzinga

08:37AM EST Cyclo Therapeutics Names Russ Belden Acting Chief Commercial Officer RTTNews

08:35AM EST Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer Business Wire

Mar 9, 2021

10:41AM EST Cyclo Therapeutics Receives Positive EMA Pediatric Committee Opinion For Trappsol Cyclo Benzinga

09:24AM EST Cyclo Gets Positive Opinion From EMA Committee On RTTNews

09:19AM EST Cyclo Therapeutics Reports Received Positive Opinion From Paediatric Committee Of European Medicines Agency On Deal Of Paediatric Investigation Plan For Trappsol Cyclo Benzinga

09:10AM EST Cyclo Gets Positive Opinion From Paediatric Committee Of EMA On Agreement Of PIP For Trappsol Cyclo RTTNews

09:05AM EST Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol(r) Cyclo(tm) Business Wire

Mar 4, 2021

09:14AM EST Cyclo Therapeutics Says Last Patient Completed Their Last Visit In The Phase 1/2 Study Evaluating Trappsol RTTNews

09:14AM EST Cyclo Therapeutics Announces Last Patient Last Visit In Phase 1/2 Trial Evaluating Trappsol Cyclo For Treatment Of Niemann-Pick Disease Type C Benzinga

09:10AM EST Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol(r) Cyclo(tm) for the Treatment of Niemann-Pick Disease Type C Business Wire

Mar 1, 2021

09:05AM EST Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer Business Wire

Feb 22, 2021

09:00AM EST Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families Business Wire

Feb 9, 2021

10:45AM EST Shares of Cyclo Therapeutics, Inc. (CYTH) are up more than 20% Tuesday morning after the company announced the presentation of positive data from the early stage studies of its lead drug candidate, Trappsol Cyclo in Niemann-Pick Disease Type C at the World Symposium 2021. RTTNews

08:09AM EST Cyclo Therapeutics Presents Positive Data From Clinical Development Program For Trappsol Cyclo At WORLDSymposium 2021 RTTNews

08:06AM EST Cyclo Therapeutics Highlights Presentation Of Data From Clinical Development Program For Its Lead Candidate, Trappsol Cyclo At WORLDSYmposium Benzinga

08:05AM EST Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol(r) Cyclo(tm), at WORLDSymposium 2021 Business Wire

Jan 27, 2021

08:39AM EST Cyclo Therapeutics Director Marcus Sieger Buys 10,000 @ Avg Price: $6.36 -Form 4 Benzinga

Jan 26, 2021

08:10AM EST Cyclo Therapeutics Says To Present On Its Clinical, Drug Development Program For Lead Candidate Trappsol Cyclo At WORLDSymposium 2021 Benzinga

08:00AM EST Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol(r) Cyclo(tm), at WORLDSymposium 2021 Business Wire

Jan 5, 2021

10:27AM EST Mid-Morning Market Update: Markets Edge Higher; ISM Manufacturing PMI Jumps to 60.7 Benzinga

10:19AM EST Shares of clinical stage biotechnology company Cyclo Therapeutics, Inc. (CYTH) are surging more than 45% Tuesday morning following positive efficacy data from the study of long term safety and efficacy of its lead drug candidate Trappsol Cyclo in Niemann-Pick Disease Type C (NPC). RTTNews

08:03AM EST UPDATE: Cyclo Says Has Authorization From FDA To Begin Enrollment For Phase 3 Trappsol Cyclo Trial In Early 2021 Benzinga

08:02AM EST Cyclo Therapeutics Reports Efficacy Data From Extension Protocol With Trappsol Cyclo In Patients With Niemann-Pick Disease Type C: Infusions For Up To 1 Year Showed Improvement In Disease Features Or Disease Stabilization Benzinga

08:00AM EST Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol(r) Cyclo(tm) in Patients with Niemann-Pick Disease Type C Business Wire

Dec 22, 2020

02:32PM EST Cyclo Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares of Common Stock in Connection with its Underwritten Public Offering Business Wire

Dec 18, 2020

08:07AM EST Benzinga Pro's Top 5 Stocks To Watch Friday, Dec. 18, 2020: BBVA, MGNX, FDX, AMGN, CYTH Benzinga

05:51AM EST Cyclo Therapeutics Director Francis Patrick Ostronic Reported Purchase of 30,000 Shares @ Avg Price of $4.66/Share in Form 4 Filing on Thursday Benzinga

05:51AM EST Cyclo Therapeutics Shares Spike Higher; Maxim Initiated With Buy, $12 PT Thursday Benzinga

05:50AM EST Cyclo Therapeutics Director Francis Patrick Ostronic Reported Purchase of 30,000 Shares @ Avg Price of $4.66/Share in Form 4 Filing on Thursday Benzinga

05:48AM EST Cyclo Therapeutics Shares Spike Higher; Maxim Initiated With Buy, $12 PT Thursday Night Benzinga

Dec 17, 2020

10:23AM EST Maxim Group Initiates Coverage On Cyclo Therapeutics with Buy Rating, Announces Price Target of $12 Benzinga

Dec 9, 2020

12:53PM EST Cyclo Therapeutics Prices 2.5M Unit Offering At $5/Unit Benzinga

12:52PM EST Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering Business Wire

Share